206 related articles for article (PubMed ID: 36543771)
21. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
[TBL] [Abstract][Full Text] [Related]
22. Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration.
Chebib N; Archer F; Bobet-Erny A; Leroux C; Cottin V
Sci Rep; 2018 Oct; 8(1):14698. PubMed ID: 30279475
[TBL] [Abstract][Full Text] [Related]
23. mTORC1 activation in lung mesenchyme drives sex- and age-dependent pulmonary structure and function decline.
Obraztsova K; Basil MC; Rue R; Sivakumar A; Lin SM; Mukhitov AR; Gritsiuta AI; Evans JF; Kopp M; Katzen J; Robichaud A; Atochina-Vasserman EN; Li S; Carl J; Babu A; Morley MP; Cantu E; Beers MF; Frank DB; Morrisey EE; Krymskaya VP
Nat Commun; 2020 Nov; 11(1):5640. PubMed ID: 33159078
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
25. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
[TBL] [Abstract][Full Text] [Related]
26. Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β (RARβ).
Liu HJ; Lam HC; Baglini CV; Nijmeh J; Cottrill AA; Chan SY; Henske EP
Oncogene; 2019 Dec; 38(49):7367-7383. PubMed ID: 31420607
[TBL] [Abstract][Full Text] [Related]
27. TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.
Lesma E; Ancona S; Sirchia SM; Orpianesi E; Grande V; Colapietro P; Chiaramonte E; Di Giulio AM; Gorio A
J Cell Mol Med; 2014 May; 18(5):766-79. PubMed ID: 24606538
[TBL] [Abstract][Full Text] [Related]
28. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells.
Alayev A; Sun Y; Snyder RB; Berger SM; Yu JJ; Holz MK
Cell Cycle; 2014; 13(3):371-82. PubMed ID: 24304514
[TBL] [Abstract][Full Text] [Related]
29. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.
Atochina-Vasserman EN; Abramova E; James ML; Rue R; Liu AY; Ersumo NT; Guo CJ; Gow AJ; Krymskaya VP
Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(12):L1447-54. PubMed ID: 26432869
[TBL] [Abstract][Full Text] [Related]
31. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.
Alayev A; Salamon RS; Sun Y; Schwartz NS; Li C; Yu JJ; Holz MK
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):637-46. PubMed ID: 25844891
[TBL] [Abstract][Full Text] [Related]
32. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.
Smolarek TA; Wessner LL; McCormack FX; Mylet JC; Menon AG; Henske EP
Am J Hum Genet; 1998 Apr; 62(4):810-5. PubMed ID: 9529362
[TBL] [Abstract][Full Text] [Related]
33. [
Verwer EE; Kavanagh TR; Mischler WJ; Feng Y; Takahashi K; Wang S; Shoup TM; Neelamegam R; Yang J; Guehl NJ; Ran C; Massefski W; Cui Y; El-Chemaly S; Sadow PM; Oldham WM; Kijewski MF; El Fakhri G; Normandin MD; Priolo C
Clin Cancer Res; 2018 Dec; 24(23):5925-5938. PubMed ID: 30054282
[TBL] [Abstract][Full Text] [Related]
34. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
35. ETV2 regulates PARP-1 binding protein to induce ER stress-mediated death in tuberin-deficient cells.
Shrestha S; Lamattina A; Pacheco-Rodriguez G; Ng J; Liu X; Sonawane A; Imani J; Qiu W; Kosmas K; Louis P; Hentschel A; Steagall WK; Onishi R; Christou H; Henske EP; Glass K; Perrella MA; Moss J; Tantisira K; El-Chemaly S
Life Sci Alliance; 2022 May; 5(5):. PubMed ID: 35181635
[TBL] [Abstract][Full Text] [Related]
36. Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis.
Li X; Liu X; Zhang L; Li C; Zhang E; Ma W; Fan Q; Yu JJ
Oncotarget; 2017 May; 8(22):36628-36638. PubMed ID: 28410230
[TBL] [Abstract][Full Text] [Related]
37. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.
Prizant H; Taya M; Lerman I; Light A; Sen A; Mitra S; Foster TH; Hammes SR
Endocr Relat Cancer; 2016 Apr; 23(4):265-80. PubMed ID: 26880751
[TBL] [Abstract][Full Text] [Related]
38. Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells.
Valianou M; Filippidou N; Johnson DL; Vogel P; Zhang EY; Liu X; Lu Y; Yu JJ; Bissler JJ; Astrinidis A
Sci Rep; 2019 Feb; 9(1):3015. PubMed ID: 30816188
[TBL] [Abstract][Full Text] [Related]
39. Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis.
Priolo C; Ricoult SJ; Khabibullin D; Filippakis H; Yu J; Manning BD; Clish C; Henske EP
Am J Respir Cell Mol Biol; 2015 Jul; 53(1):33-41. PubMed ID: 25780943
[TBL] [Abstract][Full Text] [Related]
40. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis.
Astrinidis A; Khare L; Carsillo T; Smolarek T; Au KS; Northrup H; Henske EP
J Med Genet; 2000 Jan; 37(1):55-7. PubMed ID: 10633137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
